Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.83 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.83 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.83 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | DPP4 | P27487 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.83 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.83 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.83 |
| ▸ | GAPDH | P04406 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | STAT6 | P42226 | 1/20 | 0.83 |
| ▸ | PI4KA | P42356 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.83 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.83 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.83 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.83 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL662450 | 0.98 | ADORA1 (0.83) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL353216 | 0.97 | ADORA3 (0.85) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL28583342 | 0.96 | ADORA1 (0.83) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL23093553 | 0.95 | ADORA3 (0.85) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL5600395 | 0.95 | ADORA3 (0.85) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL1746637 | 0.95 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL3046213 | 0.95 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL468212 | 0.95 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL3031964 | 0.95 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Vidarabine SCHEMBL7103173 | 0.95 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117467715-A | Process for simultaneously preparing D-glutamic acid and L-glutathione by multi-step enzyme method | 珠海瑞德林生物有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2023-05-11 | — | — | US | claimed |
| CN-109265696-B | Preparation method of ceramic water reducing agent | 佛山一宇卫士陶瓷材料有限公司 | 2021-08-20 | — | — | CN | claimed |
| CN-113101908-A | Hybrid ligand hierarchical pore metal organic framework material and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| WO-2021124301-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2021-06-24 | — | — | WO | claimed |
| CN-112707966-A | Protein and hierarchical pore metal-organic framework compound and preparation method and application thereof | 华南理工大学 | 2021-04-27 | — | — | CN | claimed |
| CN-102245643-A | Cosmetic composition containing acetylated oligoglucuronans | SEDERMA SA | 2011-11-16 | — | — | CN | claimed |
| EP-2367852-A1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | Sederma (FR) | 2011-09-28 | — | — | EP | claimed |
| WO-2010067327-A1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA (FR) | 2010-06-17 | — | — | WO | claimed |
| EP-4149415-B1 | SHAMPOO COMPOSITION COMPRISING ALKYL GLUCOSIDE | PROCTER & GAMBLE (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12605316-B2 | Alkenone-based formulations for topical applications | WOODS HOLE OCEANOGRAPHIC INSTITUTION (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4337333-B1 | SHAMPOO COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026047750-A1 | ODOR REMOVAL FORMULATIONS AND SUBSTRATES COMPRISING THE SAME | KRID LABS LLP (IN) | 2026-03-05 | — | — | WO | disclosed |
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| EP-0852949-A2 | Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation | SHISEIDO COMPANY LIMITED (JP) | 1998-07-15 | — | — | EP | disclosed |
| EP-0815838-A2 | External skin treatment composition | SHISEIDO COMPANY, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0779097-A1 | EMULSION COMPOSITION | SHISEIDO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| US-4916078-A | SUPERIMPOSING FORCE ON FLUID FLOW | BOEHRINGER MANNHEIM GMBH (DE) | 1990-04-10 | — | — | US | disclosed |
| US-4898832-A | Process for carrying out analytical determinations and means for carrying out this process | BOEHRINGER MANNHEIM GMBH (DE) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605316-B2 | Alkenone-based formulations for topical applications | CUTA, FLNA, TELO2 | ADORA1 742/4885ADORA3 936/4885ADORA2A 1990/4885 |
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | ADORA1 223/4885ADORA3 191/4885ADORA2A 143/4885 |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | UACA, TNF, TPMT | ADORA1 1287/4885ADORA3 3174/4885ADORA2A 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.